AICPI
NBRV

ABG Innovation Capital Partners III’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

ABG Innovation Capital Partners III’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,834
Closed -$8K – 6
2022
Q2 		$8K Hold
1,834
– – 0.6% 5
2022
Q1 		$19K Hold
1,834
– – 1.3% 5
2021
Q4 		$27K Hold
1,834
– – 1.56% 6
2021
Q3 		$55K Hold
1,834
– – 2.29% 6
2021
Q2 		$62K Hold
1,834
– – 0.21% 7
2021
Q1 		$76K Hold
1,834
– – 0.04% 6
2020
Q4 		$111K Buy
+1,834
New +$199K 0.07% 7

Other funds holding NBRV

VFA
Values First Advisors Gray, Tennessee $219M AUM 33.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ABG Innovation Capital Partners III's NBRV Position: Q3 2022 in Review

ABG Innovation Capital Partners III sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q3 2022, closing a stake of 1,834 shares — an estimated $8K sold.

ABG Innovation Capital Partners III first reported a position in NBRV in Q4 2020 and held it in 7 quarters. The position peaked at $111K in Q4 2020. 13 funds tracked by Wall St. Rank hold NBRV as of Q3 2022.

  • ABG Innovation Capital Partners III reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q3 2022 after selling out during the quarter.
  • ABG Innovation Capital Partners III sold 1,834 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q3 2022, an estimated $8K.
  • ABG Innovation Capital Partners III first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2020 and held it in 7 quarters.
  • ABG Innovation Capital Partners III's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $111K in Q4 2020.
  • 13 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q3 2022.

Based on ABG Innovation Capital Partners III's 13F filing for Q3 2022, filed 14 Nov 2022.